Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2022
Merus reports fourth-quarter and full-year 2021 results
Merus announced financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update. The release reported that Merus ended 2021 with $430.7 million in cash, cash equivalents and marketable securities.
2022
Merus appoints Shannon Campbell chief commercial officer
Merus appointed Shannon Campbell as executive vice president and chief commercial officer in February 2022. The source says she will lead the commercial strategy for Merus's most advanced clinical candidate, Zeno, and its pipeline of multispecific product candidates.
2020
Merus announces it will not continue MCLA-117 dose-expansion enrollment
Merus reported limited clinical activity for MCLA-117 and announced that it would not continue enrollment in the trial's planned dose-expansion cohorts. It said findings from the trial would inform development of its CD3 T-cell engager platform.
2019
Merus prices public offering of common shares
Merus announced the pricing of an underwritten public offering of 4,750,000 common shares at $14.50 per share and granted underwriters a 30-day option to purchase additional shares. The offering was expected to close on or about November 7, 2019, subject to customary closing conditions.